Abstract
Angiogenesis is a complex biological process involving the coordinated modulation of many genes. Histone deacetylases (HDAC) are a growing family of enzymes that mediate the availability of chromatin to the transcriptional machinery. Trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA), two HDAC inhibitors known to relieve gene silencing, were evaluated as potential antiangiogenic agents. TSA and SAHA were shown to prevent vascular endothelial growth factor (VEGF)-stimulated human umbilical cord endothelial cells (HUVEC) from invading a type I collagen gel and forming capillary-like structures. SAHA and TSA inhibited the VEGF-induced formation of a CD31-positive capillary-like network in embryoid bodies and inhibited the VEGF-induced angiogenesis in the CAM assay. TSA also prevented, in a dose-response relationship, the sprouting of capillaries from rat aortic rings. TSA inhibited in a dose-dependent and reversible fashion the VEGF-induced expression of VEGF receptors, VEGFR1, VEGFR2, and neuropilin-1. TSA and SAHA upregulated the expression by HUVEC of semaphorin III, a recently described VEGF competitor, at both mRNA and protein levels. This effect was specific to endothelial cells and was not observed in human fibroblasts neither in vascular smooth muscle cells. These observations provide a conspicuous demonstration that HDAC inhibitors are potent anti-angiogenic factors altering VEGF signaling.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Angelov L, Salhia B, Roncari L, McMahon G, Guha A . 1999 Cancer Res. 59: 5536–5541
Arapshian A, Kuppumbatti YS, Mira-y-Lopez R . 2000 Oncogene 19: 4066–4070
Blacher S, Devy L, Burbridge MF, Roland G, Tucker G, Noel A, Foidart JM . 2001 Angiogenesis 4: 133–142
Boehm T, Folkman J, Browder T, O'Reilly MS . 1997 Nature 390: 404–407
Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks AP, Richon VM . 2000 Cancer Res. 60: 5165–5170
Deroanne CF, Colige AC, Nusgens BV, Lapiere CM . 1996 Exp. Cell Res. 224: 215–223
Deroanne CF, Hajitou A, Calberg-Bacq CM, Nusgens BV, Lapiere CM . 1997 Cancer Res. 57: 5590–5597
Deroanne CF, Lapière CM, Nusgens BV . 2001 Cardiovasc Res. 49: 647–658
Fisher C, Gilbertson-Beadling S, Powers EA, Petzold G, Poorman R, Mitchell MA . 1994 Dev. Biol. 162: 499–510
Futamura M, Monden Y, Okabe T, Fujita-Yoshigaki J, Yokoyama S, Nishimura S . 1995 Oncogene 10: 1119–1123
Glick RD, Swendeman SL, Coffey DC, Rifkind RA, Marks PA, Richon VM, La Quaglia MP . 1999 Cancer Res. 59: 4392–4399
Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T . 1993 J. Biol. Chem. 268: 22429–22435
Kim MS, Kwon HJ, Lee YM, Baek JH, Jang J-E, Lee S-W, Moon E-J, Kim H-S, Lee S-K, Chung HY, Kim CW, Kim K-W . 2001 Nature Med. 7: 437–443
Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M . 1999 J. Cell Biol. 146: 233–242
Nervi C, Borello U, Fazi F, Buffa V, Pelicci PG, Cossu G . 2001 Cancer Res. 61: 1247–1249
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z . 1999 FASEB J. 13: 9–22
Nicosia RF, Ottinetti A . 1990 Lab. Invest. 63: 115–122
Niki T, Rombouts K, De Bleser P, De Smet K, Rogiers V, Schuppan D, Yoshida M, Gabbiani G, Geerts A . 1999 Hepatology 29: 858–867
Pepper MS, Mandriota SJ, Vassalli JD, Orci L, Montesano R . 1996 Curr. Top. Microbiol. Immunol. 213: 31–67
Ribatti D, Gualandris A, Bastaki M, Vacca A, Iurlaro M, Roncali L, Presta M . 1997 J. Vasc. Res. 34: 455–463
Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA . 1998 Proc. Natl. Acad. Sci. USA 95: 3003–3007
Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM . 1999 Cancer Res. 59: 5412–5416
Shen BQ, Lee DY, Gerber HP, Keyt BA, Ferrara N, Zioncheck TF . 1998 J. Biol. Chem. 273: 29979–29985
Shimizu M, Murakami Y, Suto F, Fujisawa H . 2000 J. Cell Biol. 148: 1283–1294
Struhl K . 1998 Genes Dev. 12: 599–606
Vittet D, Prandini MH, Berthier R, Schweitzer A, Martin-Sisteron H, Uzan G, Dejana E . 1996 Blood 88: 3424–3431
Wang J, Saunthararajah Y, Redner RL, Liu JM . 1999 Cancer Res. 59: 2766–2769
Yoshida M, Kijima M, Akita M, Beppu T . 1990 J. Biol. Chem. 265: 17174–17179
Acknowledgements
We are grateful to Christian Dani for the kind gift of ES CGR8 cells and to Clotilde Gimond, Sandrine Marchetti and Christine Bourcier (CNRS-UMR6543, J Pouysségur) for help with EB cultures, to M Tessier-Lavigne for the kind gift of semaphorin-III probe and to Marie-Jeanne Nix and Antoine Heyeres for excellent technical assistance. This work received financial support from the Belgian FNRS, the ‘Centre Anticancéreux près l'Université de Liège' and the FNRS-Télévie. C Deroanne is a Postdoctoral Researcher of the FNRS and A Colige is a Research Associate of the FNRS.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deroanne, C., Bonjean, K., Servotte, S. et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21, 427–436 (2002). https://doi.org/10.1038/sj.onc.1205108
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205108
Keywords
This article is cited by
-
Synthesis and Anticancer Potential of New Hydroxamic Acid Derivatives as Chemotherapeutic Agents
Applied Biochemistry and Biotechnology (2022)
-
Differential molecular mechanistic behavior of HDACs in cancer progression
Medical Oncology (2022)
-
Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity
Clinical Epigenetics (2021)
-
Hemodynamics mediated epigenetic regulators in the pathogenesis of vascular diseases
Molecular and Cellular Biochemistry (2021)
-
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879
Investigational New Drugs (2021)